Companies › NX Development
1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Sep 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Gleolan Prodrug metabolized to Protoporphyrin IX (PpIX) for fluorescence-guided visualization of t | – | Phase 3 | Ovarian Cancer | Sep 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05804370 | Gleolan | Phase 3 | Ovarian Cancer | Oncology | Sep 2028 |
No annotated target.
–
Verity Pharmaceuticals SecuraBio Fidia Farmaceutici Sumitomo Pharma Switzerland Eleison Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.